Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Lung Cancer Clinical Trials

A listing of Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found (241) clinical trials

Study of SRF388 in Patients With Advanced Solid Tumors

This is a Phase 1, open-label, first-in-human (FIH), dose-escalation monotherapy, safety, and expansion study of SRF388, a monoclonal antibody targeting IL-27, that will be conducted in 3 parts Part A: SRF388 monotherapy dose-escalation cohort in patients with advanced solid tumors. Part B: SRF388 monotherapy clear cell renal cell carcinoma (ccRCC) …

Phase

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

PRIMARY OBJECTIVE: I. To assess the maximum tolerated dose (MTD) of paclitaxel via intraperitoneal route in subjects with gastric or gastroesophageal cancer and positive cytology or carcinomatosis. SECONDARY OBJECTIVES: I. Safety and tolerability of escalating doses of intraperitoneal paclitaxel in subjects with gastric or gastroesophageal cancer and positive cytology or …

Phase

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

The target populations for this phase I study with TBI-1301 are patients with advanced solid tumors. Patients' tumors will be required to express NY-ESO-1, which include but is not limited to ovarian cancer, synovial sarcoma, esophageal cancer, lung cancer, bladder cancer, liver cancer, and malignant melanoma. Patients must be positive …

Phase

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of sirolimus followed by durvalumab as neoadjuvant treatment II. To evaluate the efficacy of sirolimus followed by durvalumab as neoadjuvant treatment for stage I, II, and IIIA non-small cell lung cancer (NSCLC) SECONDARY OBJECTIVES: I. To evaluate the efficacy of sirolimus …

Phase

AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma

This study plans to enroll 5 patients to assess the safety of C-TCR055. Subjects who meet the eligibility criteria will receive a single dose of C-TCR055 injection, and will be followed up post treatment for safety monitoring. The follow up period will last 12 months.

Phase

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

This study has two parts: dose escalation and dose expansion. The primary objectives are: For Dose Escalation, to assess the safety and tolerability of U3-1402 in the study population and to determine the recommended dose for expansion of U3-1402 in the study population For Dose Expansion, to investigate the antitumor …

Phase

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

This is a Phase 1b, multi-center, open-label study with a dose-escalation part and a dose expansion part. The duration of the study participation for each patient is defined as the time from the date of signed written informed consent to the completion of the follow-up period, withdrawal of consent, loss …

Phase

Nivolumab in Treating Patients With Autoimmune Disorders or Advanced Metastatic or Unresectable Cancer

PRIMARY OBJECTIVES: I. To assess the overall safety, including the incidence of dose-limiting toxicity (DLT), and other toxicities associated with the use of the anti-programmed death 1 (PD-1) antibody nivolumab in patients with varying severity of dermatomyositis (DM)/systemic sclerosis (SSc), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), inflammatory bowel disease …

Phase

An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing Recurrent Non-Small Cell Lung Cancer

This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.

Phase

Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

This is a first-in-human, open-label, non-randomized, 4-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda).

Phase